Wahed FTSE USA Shariah ETF vs Koninklijke Philips NV — how do they compare? Wahed FTSE USA Shariah ETF trades at $76 (market cap $1.00B), while Koninklijke Philips NV trades at $24.11 (market cap $23.52B). The key difference: Koninklijke Philips NV is far larger — about 23.5× Wahed FTSE USA Shariah ETF's market cap, and Koninklijke Philips NV pays a 4.17% dividend while Wahed FTSE USA Shariah ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Wahed FTSE USA Shariah ETF for 65 Days and Koninklijke Philips NV for 84 Days on average.
| HLAL | PHG | |
|---|---|---|
Market Cap | $1.00B | $23.52B |
Volume | 51,137 | 1,635,069 |
Sector | Sector/Thematic | Health |
52-Week High | $76.54 | $32.91 |
52-Week Low | $57.46 | $23.81 |
Typical Hold Time | 65 Days | 84 Days |
Enterprise Value | — | $29.87B |
Dividend Yield | — | 4.17% |
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $76.44, down 0.13% with limited daily movement. The technical picture shows bullish momentum with strong moving average support, though RSI levels above 70 indicate potential overbought conditions. Support and resistance cluster tightly around $76-77, suggesting a critical price zone. Recent corporate actions include a $0.10 dividend scheduled for September 2026.
The stock faces valuation uncertainty with key financial ratios unavailable, requiring deeper fundamental analysis. Technical strength supports near-term upside, but overbought signals and lack of current financial metrics present investment challenges. Investors need updated earnings reports and analyst coverage to assess the company's financial health and growth prospects accurately.
PHG trades at $24.225, up 0.56% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895 million in 2025 after previous losses, supported by strong operational cash flow of $1.17 billion. Recent news highlights Philips' innovation in healthcare technology including new product launches and strategic partnerships.
While valuation appears reasonable with P/E of 18.94 and EV/EBITDA of 8.86, the stock faces headwinds from bearish technical indicators and mixed analyst sentiment. Investment opportunity lies in continued earnings momentum and healthcare technology leadership, balanced against competitive pressures and execution risks in a challenging market environment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →